TELEPHONE: 512/474-5201
FACSIMILE: 512/536-4598
WRITER'S INTERNET ADDRESS:
GSHISHIMA@FULBRIGHT.COM

WRITER'S DIRECT DIAL NUMBER:
512/536-3081

FULBRIGHT & JAWORSKI L.L.P.
A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701

HOUSTON
WASHINGTON, D.C.
AUSTIN
SAN ANTONIO
DALLAS
NEW YORK
LOS ANGELES
MINNEAPOLIS
LONDON
HONG KONG

0300
#8

January 30, 2002

FILE: UTSC:671US

CERTIFICATE OF MAILING
37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

January 30, 2002 — Date

Gina N. Shishima

Commissioner for Patents
Washington, DC 20231

RE: *SN 09/978,318 "WWOX: A TUMOR SUPPRESSOR GENE MUTATED IN MULTIPLE CANCERS" – C. Marcelo Aldaz and Andrzej Bednarek*

Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references (B1-B2, C1-C46).

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10109289/GNS.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Gina N. Shishima
Reg. No. 45,104

GNS/cmb
Encl: as noted

25114553.1

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:
C. Marcelo Aldaz
Andrzej Bednarek

Serial No.: 09/978,318

Filed: October 15, 2001

For: WWOX: A TUMOR SUPPRESSOR GENE MUTATED IN MULTIPLE CANCERS

Group Art Unit: Unknown

Examiner: Unknown

Atty. Dkt. No.: UTSC:671US/GNS

CERTIFICATE OF MAILING
37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

January 30, 2002
Date

Gina N. Shishima

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10109289/GNS.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Gina N. Shishima
Reg. No. 45,104
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: January 30, 2002

Form PTO-1449 (modified)	Atty. Docket No. UTSC:671US/GNS	Serial No. 09/978,318
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant C. Marcelo Aldaz Andrzej Bednarek	
	Filing Date: October 15, 2001	Group: Unknown

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1						

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	PQ 4711	12/16/99	Australian Prov. Patent App.			
	B2	WO 01/44466	6/21/01	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Aldaz *et al.*, "Comparative allelotype of in situ and invasive human breast cancer: high frequency of microsatellite instability in lobular breast carcinomas," *Cancer Res.*, 55:3976-3981, 1995.
	C2	Andre and Springael, "WWP, a new amino acid motif present in single or multiple copies in various proteins including dystrophin and the SH3-binding Yes- associated protein YAP65," *Biochem. Biophys. Res. Commun.*, 205(2):1201-1205, 1994.
	C3	Bedford *et al.*, "WW domain-mediated interactions reveal a spliceosome-associated protein that binds a third class of proline-rich motif: the proline glycine and methionine-rich motif," *Proc. Natl. Acad. Sci. USA*, 95:10602-10607, 1998.
	C4	Bednarek and Aldaz, "Characterization of transcripts from a commonly deleted area of chromosome 16 (q23.3-q24.1) in human breast cancer," *Proc. Amer. Assoc. Cancer Res.*, 39:128, #872, 1998.
	C5	Bednarek *et al.*, "WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer," *Cancer Res.*, 60:2140-2145, 2000.
	C6	Bednarek *et al.*, "WWOX, the FRA16D gene, behaves as a suppressor of tumor growth," *Cancer Res.*, 61:8068-8073, 2001.

25094759.1

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. UTSC:671US/GNS	Serial No. 09/978,318
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	**Applicant** C. Marcelo Aldaz Andrzej Bednarek	
	Filing Date: October 15, 2001	**Group:** Unknown

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C7	Bork and Sudol, "The WW domain: a signalling site in dystrophin?" *Trends Biochem. Sci.*, 19:531-533, 1994.
	C8	Carter *et al.*, "Allelic loss of chromosomes 16q and 10q in human prostate cancer," *Proc. Natl. Acad. Sci. USA*, 87: 8751-8755, 1990
	C9	Chan *et al.*, "Formin binding proteins bear WWP/WW domains that bind proline-rich peptides and functionally resembel SH3 domains," *EMBO J.*, 15(5):1045-1054, 1996.
	C10	Chang *et al.*, "Hyaluronidase induction of a WW domain-containing oxidoreductase that enhanced tumor necrosis factor cytotoxicity," *J. Biol. Chem.*, 276:3361-3370, 2001.
	C11	Chen and Sudol, "The WW domain of Yes-associated protein binds a proline-rich ligand that differs from the consensus established for Src homology 3-binding modules," *Proc. Natl. Acad. Sci. USA*, 92:7819-7823, 1995.
	C12	Chen *et al.*, "Deletion map of chromosome 16q in ductal carcinoma in situ of the breast: refining a putative tumor suppressor gene region," *Cancer Res.* 56:5605-5609, 1996.
	C13	Chesi *et al.*, "Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma," *Blood,* 91:4457-4463, 1998.
	C14	Cleton-Jansen *et al.*, "At least two different regions are involved in allelic imbalance on chromosome arm 16q in breast cancer," *Genes, Chromos, Cancer*, 9:101-107, 1994.
	C15	Crawford *et al.*, "The PISSLRE gene: structure, exon skipping, and exclusion as tumor suppressor in breast cancer," *Genomics*, 56:90-97, 1999.
	C16	Duax and Ghosh, "Structure and function of steroid dehydrogenases involved in hypertension, fertility, and cancer," *Steroids*, 62:95-100, 1997.
	C17	Dutrillaux *et al.*, "Characterization of chromosomal anomalies in human breast cancer. A comparison of 30 paradiploid cases with few chromosome changes," *Cancer Genet. Cytogenet.*, 49:203-217, 1990.
	C18	GenBank Accession Number AF179633
	C19	GenBank Accession Number AF211943
	C20	GenBank Accession Number AF212843
	C21	GenBank Accession Number AF227526

25094759.1

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. UTSC:671US/GNS	Serial No. 09/978,318
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant C. Marcelo Aldaz Andrzej Bednarek	
	Filing Date: October 15, 2001	Group: Unknown

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C22	GenBank Accession Number AF227527
	C23	GenBank Accession Number AF227528
	C24	GenBank Accession Number AF395123
	C25	GenBank Accession Number AF395124
	C26	GenBank Accession Number U13395, locus ID 9621
	C27	Jornvall *et al.*, "Short-chain dehydrogenases/reductases (SDR)," *Biochemistry,* 34:6003-6013, 1995.
	C28	Krummel *et al.*, "The characterization of the common fragile site FRA16D and its involvement in multiple myeloma translocations," *Genomics*, 69:37-46, 2000.
	C29	Lu *et al.*, "Function of WW domains as phosphoserine- or phosphothreonine-binding modules," *Science*, 283:1325-1328, 1999.
	C30	Mangelsdorf *et al.*, "Chromosomal fragile site FRA16D and DNA instability in cancer," *Cancer Res.*, 60: 1683-1689, 2000.
	C31	Paige *et al.*, "A 700-kb physical map of a region of 16q23.2 homozygously deleted in multiple cancers and spanning the common fragile site FRA16D," *Cancer Res.* 60:1690-1697, 2000.
	C32	Paige *et al.*, "WWOX: A candidate tumor suppressor gene involved in multiple tumor types," *Proc. Natl. Acad. Sci. USA*, 98:11417-11422, 2001
	C33	Pandis *et al.*, "Whole-arm t(1;16) and i(1q) as sole anomalies identify gain of 1q as a primary chromosomal abnormality in breast cancer," *Genes Chromosomes Cancer*, 5:235-238, 1992.
	C34	Price *et al.*, "Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice," *Cancer Res.* 50:717-721, 1990.
	C35	Richards, "Fragile and unstable chromosomes in cancer: causes and consequences," *Trends Genet.*, 17:339-345, 2001.
	C36	Ried *et al.*, "Common chormosomal fragile site FRA16D sequence: identification of the FOR gene spanning FRA16D and homozygous deletions and translocation breakpoints in cancer cells,""*Human Molecular Genetics*, 9(11):1651-1663, 2000.

25094759.1

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. UTSC:671US/GNS	Serial No. 09/978,318
List of Patents and Publications for Applicant's	Applicant C. Marcelo Aldaz Andrzej Bednarek	
INFORMATION DISCLOSURE STATEMENT	Filing Date: October 15, 2001	Group: Unknown
(Use several sheets if necessary)		

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C37	Sato *et al.*, "Allelotype of breast cancer: cumulative allele losses promote tumor progression in primary breast cancer," *Cancer Res.*, 50:7184-7189, 1990.
	C38	Savino *et al.*, "Characterization of copine VII, a new member of the copine family, and its exclusion as a candidate in sporadic breast cancers with loss of heterozygosity at 16q24.3," *Genomics*, 61:219-226, 1999.
	C39	Smith *et al.*, "Common fragile sites and cancer (Review)," *Int. J. Oncol.*, 12:187-196, 1998.
	C40	Staub *et al.*, "WW domains of Nedd4 bind to the proline-rich PY motifs in the epithelial Na+ channel deleted in Liddle's syndrome," *Embo. J.*, 15:2371-2380, 1996.
	C41	Sudol and Hunter, "NeW wrinkles for an old domain," *Cell*, 103:1001-1004, 2000.
	C42	Sudol *et al.*, "Characterization of the mammalian YAP (Yes-associated protein) gene and its role in defining a novel protein module, the WW domain," *J. Biol. Chem.*, 270:14733-14741, 1995.
	C43	Sudol, "Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product," *Oncogene*, 9:2145-2152, 1994.
	C44	Sutherland *et al.*, "Fragile sites still breaking," *Trends Genet.*, 14:501-506, 1998.
	C45	Tsuda *et al.*, "Allele loss on chromosome 16q24..2-qter occurs frequently in breast cancer irrespectively of differences in phenotype and extent of spread," *Cancer Res.*, 54: 513-517, 1994.
	C46	Whitmore *et al.*, "Construction of a high-resolution physical and transcription map of chromosome 16q24.3: a region of frequent loss of heterozygosity in sporadic breast cancer," *Genomics*, 50:1-8, 1998.

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.